Double maintains 3 strategies that include BCRX - BioCryst Pharmaceuticals, Inc.
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| SGOV | 0.08% | $50.93B | 0.09% |
| AVIG | -0.11% | $1.10B | 0.15% |
| IBDS | 0.13% | $3.14B | 0.1% |
| USCI | 0.14% | $244.88M | 1.07% |
| JPLD | -0.15% | $2.06B | 0.24% |
| CTA | -0.16% | $1.08B | 0.76% |
| WEAT | -0.16% | $123.28M | 0.28% |
| PDBC | 0.21% | $4.52B | 0.59% |
| BSMR | -0.24% | $258.51M | 0.18% |
| PYLD | 0.28% | $6.03B | 0.69% |
| IUSB | 0.45% | $32.69B | 0.06% |
| DBC | -0.49% | $1.27B | 0.87% |
| ICSH | 0.52% | $5.96B | 0.08% |
| ISTB | -0.54% | $4.41B | 0.06% |
| VTIP | -0.55% | $15.15B | 0.03% |
| GSG | -0.55% | $1.02B | 0.75% |
| JMUB | 0.55% | $3.06B | 0.18% |
| BLV | -0.58% | $5.58B | 0.03% |
| IBMS | 0.59% | $89.61M | 0.18% |
| TAXF | 0.62% | $477.91M | 0.29% |
Yahoo
BioCryst Pharmaceutical Inc. (NASDAQ:BCRX) is one of the 13 Best Healthcare Stocks to Buy Under $10. On July 7, RBC Capital analyst Brian Abrahams maintained a Buy rating on BioCryst Pharmaceutical Inc. (NASDAQ:BCRX) and set a price target of $13.00. The same day, the company also announced the appointment of Babar Ghias as Chief Financial Officer and […]
Yahoo
RESEARCH TRIANGLE PARK, N.C., July 09, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present new findings from patient-focused research highlighting the burden of current treatments for HAE on pediatric patients under the age of 12 and their caregivers and perspectives on the importance of HAE treatments. The findings will be presented in posters at the 2025 US HAEA National Summit in Baltimore, which is taking place July 10-13, 2025
Finnhub
Island Pharmaceuticals Ltd: Acquisition of Galidesivir antiviral program from Biocryst Pharmaceuticals Deal completed for base purchase price of $550,000...
Yahoo
Here is how BioCryst Pharmaceuticals (BCRX) and Cardinal Health (CAH) have performed compared to their sector so far this year.
Yahoo
RESEARCH TRIANGLE PARK, N.C., July 07, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the appointment of Babar Ghias as chief financial officer (CFO) and head of corporate development. Mr. Ghias joins BioCryst from AvenCell Therapeutics, a clinical-stage CAR-T company focused on hematologic malignancies, where he served as CFO since 2022. “Babar brings extensive deal making and operational experience in addition to his previous roles as a CFO at rare disea
Finnhub
BioCryst Pharmaceuticals, Inc. announced the appointment of Babar Ghias as chief financial officer . Mr. Ghias joins BioCryst from AvenCell Therapeutics, a clinical-stage CAR-T company focused on...
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| XBI | 47.92% | $4.81B | 0.35% |
| PBE | 47.16% | $226.91M | 0.58% |
| IBB | 45.10% | $5.37B | 0.45% |
| GNOM | 43.92% | $46.47M | 0.5% |
| XPH | 41.93% | $150.58M | 0.35% |
| BBH | 40.79% | $339.54M | 0.35% |
| PTH | 40.04% | $96.25M | 0.6% |
| PINK | 39.43% | $130.30M | 0.5% |
| IAT | 39.24% | $620.27M | 0.4% |
| KRE | 39.24% | $3.65B | 0.35% |
| KBE | 38.88% | $1.56B | 0.35% |
| IWC | 38.88% | $840.86M | 0.6% |
| FBT | 38.70% | $1.02B | 0.54% |
| ARKG | 38.46% | $1.03B | 0.75% |
| VTWO | 38.41% | $12.65B | 0.07% |
| IWM | 38.33% | $65.64B | 0.19% |
| KBWB | 38.16% | $4.80B | 0.35% |
| GSSC | 37.96% | $591.16M | 0.2% |
| IWO | 37.61% | $11.77B | 0.24% |
| IWN | 37.48% | $11.34B | 0.24% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| TAIL | -27.12% | $94.86M | 0.59% |
| BTAL | -21.43% | $315.93M | 1.43% |
| VIXY | -18.79% | $184.73M | 0.85% |
| GBIL | -13.08% | $6.36B | 0.12% |
| FTSD | -12.14% | $233.11M | 0.25% |
| IBTG | -12.10% | $1.92B | 0.07% |
| ULST | -11.72% | $592.38M | 0.2% |
| XHLF | -11.49% | $1.73B | 0.03% |
| IVOL | -11.11% | $342.69M | 1.02% |
| SPTS | -10.91% | $5.77B | 0.03% |
| AGZ | -10.66% | $609.66M | 0.2% |
| UTWO | -10.18% | $376.33M | 0.15% |
| CLIP | -9.98% | $1.55B | 0.07% |
| SHYM | -9.65% | $355.86M | 0.35% |
| IBTI | -9.54% | $1.06B | 0.07% |
| VGSH | -9.19% | $22.68B | 0.03% |
| IBTM | -9.18% | $316.60M | 0.07% |
| IBTH | -9.11% | $1.62B | 0.07% |
| IEI | -9.07% | $15.53B | 0.15% |
| SCHO | -9.03% | $10.98B | 0.03% |
Current Value
$8.871 Year Return
Current Value
$8.871 Year Return
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CRNX | 40.36% | $3.00B | -39.42% | 0.00% |
| FBK | 40.19% | $2.55B | +13.78% | 1.52% |
| PPBI | 40.04% | $2.22B | -7.72% | 5.85% |
| SFBS | 40.02% | $4.51B | +22.73% | 1.60% |
| IMMP | 39.77% | $239.50M | -18.41% | 0.00% |
| TFC | 39.54% | $59.58B | +12.65% | 4.60% |
| UCB | 39.27% | $3.85B | +17.17% | 3.06% |
| TFSL | 38.99% | $3.70B | +1.15% | 8.60% |
| ZION | 38.90% | $8.31B | +18.73% | 3.04% |
| UBSI | 38.69% | $5.43B | +12.17% | 3.90% |
| FHN | 38.57% | $11.21B | +33.45% | 2.73% |
| FITB | 38.55% | $29.40B | +15.13% | 3.39% |
| BEAM | 38.51% | $2.22B | -14.88% | 0.00% |
| FNB | 38.32% | $5.76B | +11.03% | 3.03% |
| BRKL | 38.16% | $996.19M | +20.22% | 4.87% |
| DNLI | 38.15% | $2.23B | -33.52% | 0.00% |
| BANC | 38.12% | $2.38B | +11.83% | 2.66% |
| ABCB | 38.06% | $4.65B | +24.02% | 1.12% |
| CLDX | 37.88% | $1.51B | -40.97% | 0.00% |
| BHLB | 37.86% | $1.23B | +10.11% | 2.74% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| NTZ | 0.01% | $33.60M | -33.39% | 0.00% |
| SYPR | -0.04% | $48.49M | +14.05% | 0.00% |
| SO | 0.06% | $102.50B | +16.78% | 3.13% |
| ZCMD | 0.10% | $28.54M | -8.87% | 0.00% |
| FDP | 0.11% | $1.61B | +52.20% | 3.28% |
| FMC | 0.14% | $5.33B | -24.76% | 5.48% |
| SG | 0.19% | $1.61B | -44.78% | 0.00% |
| LITB | 0.19% | $24.26M | -71.62% | 0.00% |
| CCEC | 0.20% | $1.02B | +3.91% | 2.48% |
| CNC | -0.23% | $16.18B | -51.64% | 0.00% |
| UFI | 0.38% | $90.15M | -13.86% | 0.00% |
| NEE | -0.47% | $153.66B | -0.08% | 2.93% |
| PLUG | -0.48% | $1.93B | -42.66% | 0.00% |
| SPTN | -0.50% | $898.70M | +41.30% | 3.29% |
| CME | 0.54% | $99.17B | +44.04% | 1.75% |
| VSA | -0.59% | $8.59M | -17.17% | 0.00% |
| CYD | -0.65% | $895.94M | +159.28% | 3.79% |
| CORT | -0.66% | $7.64B | +131.02% | 0.00% |
| AMT | 0.75% | $103.46B | +6.67% | 3.01% |
| MNOV | 0.79% | $62.29M | -8.63% | 0.00% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| ZBH | -10.72% | $18.83B | -12.05% | 1.02% |
| AIFU | -8.36% | $17.40M | +87.81% | 0.00% |
| STG | -8.15% | $38.79M | -3.01% | 0.00% |
| VHC | -8.11% | $69.05M | +176.10% | 0.00% |
| PRPO | -5.88% | $23.73M | +229.04% | 0.00% |
| VZ | -5.81% | $177.21B | +1.77% | 8.05% |
| NEXA | -5.65% | $664.84M | -35.31% | 0.00% |
| CBOE | -5.49% | $24.55B | +38.09% | 1.08% |
| LFVN | -5.38% | $155.72M | +105.82% | 1.34% |
| EXC | -5.15% | $44.05B | +23.53% | 3.60% |
| TSN | -5.00% | $19.08B | -3.94% | 3.65% |
| CARV | -4.99% | $9.39M | +24.99% | 0.00% |
| IART | -4.67% | $1.02B | -56.97% | 0.00% |
| MO | -4.62% | $98.62B | +24.36% | 7.00% |
| AEP | -4.58% | $56.65B | +16.73% | 3.49% |
| TDUP | -4.50% | $807.63M | +285.88% | 0.00% |
| AQB | -3.62% | $3.04M | -56.34% | 0.00% |
| WBA | -3.39% | $10.01B | +1.14% | 4.34% |
| PEP | -2.77% | $186.58B | -17.00% | 4.07% |
| PSQH | -2.73% | $105.65M | -40.36% | 0.00% |
